TAILORx: Transforming the Treatment of Breast Cancer
The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results have been published in the New England Journal of Medicine.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
The Eighth Edition AJCC Staging Manual will go into effect in 2018, and it will change staging for T1-2 N0 M0 breast cancer patients.
Latest TAILORx Data
After 5 years, 95% of women with a low Oncotype DX Breast Recurrence Score result were recurrence-free with hormone therapy alone.
Sign up for Our Healthcare Professional Updates